Canada has now approved the drug to reduce the formation of new bone formation (heterotopic ossification) in adults and children aged 8 years and above for females and 10 years and above for males.
The pathophysiology of multiple sclerosis (MS) is characterized by demyelination, which culminates in a reduction in axonal transmission. Axonal and neuronal degeneration seem to be concomitant ...
Multiple sclerosis (MS) is a disease marked by focal demyelinating inflammatory plaques throughout the CNS. Neuro-ophthalmologic sequelae are common in MS and may arise from the disease itself or ...